Stock Analysts

T-Mobile (TMUS) Q2 Earnings Beat, Revenues Miss Estimates

T-Mobile US, Inc. TMUS reported healthy financial results in the second quarter of 2018, driven by record-high service revenues and profitability. Net Income Net income for the reported quarter came in at $782 million or 92 cents per share compared with $567 million or 67 cents per share in the year-ago quarter […]

Stock Analysts

Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track

Ophthotech Corporation OPHT incurred a loss of 37 cents per share for the second quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 40 cents and loss of 62 cents in the year-ago quarter. With no approved products in its portfolio, Ophthotech derives revenues from milestone and other payments under collaborations. However, there were no such revenues in the quarter. […]

Stock Analysts

American Water Works (AWK) Beats Earnings Estimates in Q2

American Water Works Company AWK posted second-quarter 2018 earnings per share of 83 cents, which beat the Zacks Consensus Estimate of 81 cents by 2.5%. The figure improved 13.7% year over year. The uptick was supported by solid growth in the Regulated and Market-Based businesses in the second quarter. […]

Economic Data

Markets Drop on Tariff Threats; Jobless Claims, Q2 Earnings Solid

Thursday, August 2, 2018 Like Thursday-morning clockwork, new Initial Jobless Claims for last week have been released before today’s opening bell. They further push the narrative that we are sturdily within an historically low range of new claims: 218K, up 1000 from the unrevised previous week’s 217K and keeping the 4-week average squarely within the 200-225K range that we thought impossible not all too long ago. Continuing claims have also reached new preposterously low levels: 1.724 million versus the previous week’s 1.747 million, well below the psychologically satisfying threshold of 2 million continuing claims we had seen not all too long ago […]

Technicals

Intercept (ICPT) Q2 Loss Narrower-Than-Expected

New York-based Intercept Pharmaceuticals, Inc . ICPT focused on bringing novel therapeutics to treat chronic liver diseases to market. Intercept received a major boost with the FDA approval (in May 2016) of its lead drug, Ocaliva, in combination with ursodeoxycholic (UDCA), for the treatment of primary biliary cholangitis (PBC) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA […]